DIBROMODULCITOL (cas 10318-26-0), mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer

Add time:08/02/2019    Source:sciencedirect.com

A combination of dibromodulcitol 500 mg orally, mitomycin C 10 mg i.v. and vinblastine 10 mg i.v. all given on day 1 and repeated every 4 weeks was given to 40 patients with advanced breast cancer. All but one had received previous endocrine therapy. The response rate (CR + PR) in 24 previously untreated patients was 66% and was 37% in 16 previously treated patients. The survival of responders was significantly longer than non-responders. Thirty-two per cent of patients experienced nausea and vomiting. There was little myelosuppression or thrombocytopenia on the day of starting a new course of therapy but the haemoglobin dropped by 2 g/dl in 32% of patients during therapy. Thus DMV is a relatively non-toxic active regimen for patients with advanced breast cancer.

We also recommend Trading Suppliers and Manufacturers of DIBROMODULCITOL (cas 10318-26-0). Pls Click Website Link as below: cas 10318-26-0 suppliers

Prev:APOPTOTIC AND MITOTIC ACTIVITY IN SQUAMOUS CELL CARCINOMA CELLS AFTER COMBINED MODALITY TREATMENT WITH γ-IRRADIATION AND DIBROMODULCITOL (cas 10318-26-0)
Next:The distribution of bromine content of DIBROMODULCITOL (cas 10318-26-0) in the central nervous system of patients with malignant gliomas)